

Q2 2015 results

Progressing our transformation to a leading global biotech, whilst upgrading full year earnings guidance

July 23, 2015



Flemming Orn
CEO

Jeff Poulton
CFO

NPS EX. 2114
CFAD v. NPS
IPR2015-01093

“SAFE HARBOR” statement under the Private Securities Litigation Reform Act of 1995

Statements included in this announcement that are not historical facts, including without limitation statements concerning our 10X targets, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

- Shire's products may not be a commercial success;
- product sales from ADDERALL XR[®] and INTUNIV[®] are subject to generic competition;
- the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payers in a timely manner for our products may affect future revenues, financial condition and results of operations;
- Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contract manufacturers for other products and to provide goods and services. Some of the Shire's products or ingredients are only available from a single source for manufacture. Any disruption to the supply chain for any of the Shire's products may result in Shire being unable to manufacture, market or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time;
- the manufacture of Shire's products is subject to extensive oversight by various regulatory agencies. Regulatory approvals and approvals associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increased operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
- Shire has a portfolio of products in various stages of research and development. The successful development of these products is uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approvals;
- the actions of certain customers could affect Shire's ability to sell or market products profitably. Fluctuations in buying or distribution by such customers can adversely affect Shire's revenues, financial conditions or results of operations;
- investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines;
- adverse outcomes in legal matters and other disputes, including Shire's ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations;
- Shire faces intense competition for highly qualified personnel from other companies and organizations. Shire is undergoing a reorganization and was the subject of an unsuccessful acquisition proposal and the consequent uncertainty could adversely affect Shire's ability to attract and/or retain the highly skilled personnel needed for Shire to meet its strategic objectives;
- failure to achieve Shire's strategic objectives with respect to the acquisition of NPS Pharmaceuticals, Inc. may adversely affect Shire's financial condition and results of operations;

and other risks and uncertainties detailed from time to time in Shire's filings with the US Securities and Exchange Commission, in

Our continuous transformation

2013

2014

2015

2016

2017

2018

2019

2020

Investing to create
further long-term value

2013-2015 Becoming OneShire

- Step-change in performance
- Effective and efficient organization
- Set basis for long-term growth


Building a leading global biotech company


- Creating scale and momentum
- Culture of bold innovation, internal and external
- Patient-centric Rare Disease mindset to all business

On track to meet 10x20

Q2 2015: Progress towards becoming a leading global biotechnology company

GROWTH

 Double digit CER⁽¹⁾ product sales growth excluding INTUNIV

 Non GAAP diluted earnings per ADS growth guidance increased to mid-to-high single digit percent range for the full year

 Significant investment in expected future growth drivers, including VYVANSE BED, GATTEX/REVESTIVE and NATPARA

 Continued strong growth for VYVANSE post BED launch


 GATTEX performing well; implementation of enhanced commercial plans


 Strong US launch for NATPARA in HPT

INNOVATION

 OPUS3 study for lifitegrast fu results expected Q4 2015


 Phase 3 pediatrics study for S initiated six weeks ahead of

 Positive End of Phase 2 meet for SHP620; considering prog Phase 3 in 2016

 Phase 2 data received in thre liver indications with SHP625 options for a possible path fo

Delivering double digit core product sales⁽¹⁾ growth while investing for the future

Product Sales



- Core product sales excluding INTUNIV growing 12% on a constant exchange rate basis
- Continuing to make significant investment in expected future growth drivers: VYVANSE, GATTEX/REVESTIVE and NATPARA
- H1 Non GAAP diluted earnings per ADS⁽³⁾⁽⁴⁾ up 9% on a reporting basis; 13% on a CER basis

Non GAAP diluted earnings per ADS growth guidance increased to mid-to-high single digit percent range for the full year

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.